Harrow Health, Inc. (HROW)
USD 24.4
(1.29%)
USD 24.4
(1.29%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 90.55 Million USD | 43.25% |
| 2022 | 63.21 Million USD | 16.49% |
| 2021 | 54.26 Million USD | 57.7% |
| 2020 | 34.4 Million USD | -0.02% |
| 2019 | 34.41 Million USD | 38.49% |
| 2018 | 24.85 Million USD | 87.29% |
| 2017 | 13.26 Million USD | 31.23% |
| 2016 | 10.11 Million USD | 124.19% |
| 2015 | 4.51 Million USD | 694.84% |
| 2014 | 567.4 Thousand USD | 5574.07% |
| 2013 | 10 Thousand USD | -90.0% |
| 2012 | 100 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 36.4 Million USD | 51.45% |
| 2024 Q1 | 24.03 Million USD | -4.07% |
| 2023 Q2 | 23.47 Million USD | 31.62% |
| 2023 Q1 | 17.83 Million USD | 25.9% |
| 2023 Q3 | 24.19 Million USD | 3.1% |
| 2023 FY | 90.55 Million USD | 43.25% |
| 2023 Q4 | 25.05 Million USD | 3.53% |
| 2022 Q1 | 16.15 Million USD | 6.94% |
| 2022 FY | 63.21 Million USD | 16.49% |
| 2022 Q4 | 14.16 Million USD | -12.04% |
| 2022 Q3 | 16.1 Million USD | -4.09% |
| 2022 Q2 | 16.78 Million USD | 3.91% |
| 2021 Q3 | 13.76 Million USD | 0.34% |
| 2021 FY | 54.26 Million USD | 57.7% |
| 2021 Q1 | 11.67 Million USD | 9.52% |
| 2021 Q2 | 13.71 Million USD | 17.51% |
| 2021 Q4 | 15.1 Million USD | 9.76% |
| 2020 Q1 | 8.19 Million USD | -9.38% |
| 2020 Q3 | 10.7 Million USD | 120.41% |
| 2020 FY | 34.4 Million USD | -0.02% |
| 2020 Q2 | 4.85 Million USD | -40.72% |
| 2020 Q4 | 10.65 Million USD | -0.42% |
| 2019 FY | 34.41 Million USD | 38.49% |
| 2019 Q1 | 8.39 Million USD | 15.24% |
| 2019 Q2 | 8.29 Million USD | -1.2% |
| 2019 Q3 | 8.69 Million USD | 4.86% |
| 2019 Q4 | 9.03 Million USD | 3.97% |
| 2018 Q2 | 6.22 Million USD | 29.89% |
| 2018 Q3 | 6.54 Million USD | 5.15% |
| 2018 Q4 | 7.28 Million USD | 11.21% |
| 2018 Q1 | 4.79 Million USD | 23.56% |
| 2018 FY | 24.85 Million USD | 87.29% |
| 2017 Q4 | 3.88 Million USD | 25.97% |
| 2017 Q3 | 3.08 Million USD | -13.7% |
| 2017 Q2 | 3.56 Million USD | 30.26% |
| 2017 FY | 13.26 Million USD | 31.23% |
| 2017 Q1 | 2.74 Million USD | 0.66% |
| 2016 Q4 | 2.72 Million USD | 7.93% |
| 2016 Q2 | 2.73 Million USD | 28.28% |
| 2016 Q3 | 2.52 Million USD | -7.79% |
| 2016 FY | 10.11 Million USD | 124.19% |
| 2016 Q1 | 2.13 Million USD | 37.02% |
| 2015 Q3 | 1.48 Million USD | 61.5% |
| 2015 Q4 | 1.55 Million USD | 5.06% |
| 2015 FY | 4.51 Million USD | 694.84% |
| 2015 Q1 | 556 Thousand USD | 221.82% |
| 2015 Q2 | 917 Thousand USD | 64.93% |
| 2014 Q2 | 191.15 Thousand USD | 13456.88% |
| 2014 FY | 567.4 Thousand USD | 5574.07% |
| 2014 Q4 | 172.76 Thousand USD | -14.51% |
| 2014 Q3 | 202.07 Thousand USD | 5.72% |
| 2014 Q1 | 1410.00 USD | -43.6% |
| 2013 Q4 | 2500.00 USD | 0.0% |
| 2013 FY | 10 Thousand USD | -90.0% |
| 2013 Q1 | 2500.00 USD | 0.0% |
| 2013 Q2 | 2500.00 USD | 0.0% |
| 2013 Q3 | 2500.00 USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | -100.0% |
| 2012 FY | 100 Thousand USD | 0.0% |
| 2012 Q1 | 100 Thousand USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | 34.06 Thousand USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | -100.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 72.237% |
| Embecta Corp. | 749.9 Million USD | 87.925% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 70.34% |
| Dynavax Technologies Corporation | 182.11 Million USD | 50.278% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -23.931% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 81.531% |
| PainReform Ltd. | -15 Thousand USD | 603786.667% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -204.359% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -985.875% |
| SCYNEXIS, Inc. | 124.51 Million USD | 27.277% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -16246.163% |
| Cosmos Health Inc. | 4.34 Million USD | -1981.884% |
| Journey Medical Corporation | 52.52 Million USD | -72.413% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -985.875% |
| Safety Shot Inc | -74.45 Thousand USD | 121717.847% |
| Alpha Teknova, Inc. | 10.29 Million USD | -779.497% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 78.972% |
| Bright Green Corporation | -237.01 Thousand USD | 38305.438% |
| Procaps Group, S.A. | 239.56 Million USD | 62.202% |
| Theratechnologies Inc. | 62.12 Million USD | -45.75% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -1808.388% |
| Biofrontera Inc. | 16.62 Million USD | -444.614% |
| DURECT Corporation | 6.83 Million USD | -1225.619% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 82.71% |
| Cronos Group Inc. | 6.99 Million USD | -1195.299% |
| OptiNose, Inc. | 62.35 Million USD | -45.224% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 79.474% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 29985.479% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -2864.894% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 70.77% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -1578.612% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -170.421% |
| Radius Health, Inc. | 307.71 Million USD | 70.572% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -798.532% |
| ProPhase Labs, Inc. | 16.23 Million USD | -457.627% |
| Phibro Animal Health Corporation | 312.48 Million USD | 71.022% |
| Procaps Group S.A. | 239.56 Million USD | 62.202% |
| Alvotech | -69.42 Million USD | 230.438% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -6854.916% |
| Viatris Inc. | 6.43 Billion USD | 98.594% |
| Rockwell Medical, Inc. | 8.7 Million USD | -940.361% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -65.891% |
| SIGA Technologies, Inc. | 122.09 Million USD | 25.832% |
| Tilray Brands, Inc. | 223.35 Million USD | 59.457% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -116.375% |
| Shineco, Inc. | 882.16 Thousand USD | -10164.825% |
| PetIQ, Inc. | 252.74 Million USD | 64.171% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 12245.179% |
| Incannex Healthcare Limited | 12 Thousand USD | -754508.333% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 95.098% |
| Alimera Sciences, Inc. | 61.17 Million USD | -48.035% |
| Silver Spike Investment Corp. | 8.1 Million USD | -1017.58% |
| Assertio Holdings, Inc. | 125.04 Million USD | 27.586% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 1329611.085% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -2060.567% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -1281.223% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 3857.112% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -233.934% |
| Hempacco Co., Inc. | -1.21 Million USD | 7547.816% |
| Talphera, Inc. | -4.89 Million USD | 1949.908% |
| Alvotech | -69.42 Million USD | 230.438% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 59.15% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 87.238% |
| Currenc Group, Inc. | 17.35 Million USD | -421.73% |
| Kamada Ltd. | 52.59 Million USD | -72.178% |
| Indivior PLC | 907 Million USD | 90.016% |
| Evoke Pharma, Inc. | 4.97 Million USD | -1718.789% |
| Flora Growth Corp. | 17.73 Million USD | -410.503% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 3857.112% |
| Evolus, Inc. | 140.52 Million USD | 35.561% |
| HUTCHMED (China) Limited | 453.55 Million USD | 80.035% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 73.674% |
| Akanda Corp. | 111.44 Thousand USD | -81150.617% |